M
Michael B. Sporn
Researcher at Dartmouth College
Publications - 561
Citations - 96644
Michael B. Sporn is an academic researcher from Dartmouth College. The author has contributed to research in topics: Transforming growth factor & Transforming growth factor beta. The author has an hindex of 157, co-authored 559 publications receiving 94605 citations. Previous affiliations of Michael B. Sporn include Cornell University & Reata Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Complementary deoxyribonucleic acid cloning of a novel transforming growth factor-beta messenger ribonucleic acid from chick embryo chondrocytes.
TL;DR: Using a human TGF beta 1 cDNA probe, two distinct TGF Beta RNAs are detected in cultured primary chick embryo chondrocytes and one of these RNAs shows similarity to mammalian TGFbeta 1.
Journal ArticleDOI
Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis.
Arie Neymotin,Noel Y. Calingasan,Elizabeth Wille,Nima N. Naseri,Susanne Petri,Maria Damiano,Karen T. Liby,Renee Risingsong,Michael B. Sporn,M. Flint Beal,Mahmoud Kiaei,Mahmoud Kiaei +11 more
TL;DR: Two triterpenoid compounds that activate the Nrf2/ARE signaling pathway may be useful in the treatment of ALS and significantly attenuated weight loss, enhanced motor performance, and extended the survival of G93A SOD1 mice.
Journal ArticleDOI
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
Umberto Veronesi,Luigi Mariani,Andrea Decensi,Franca Formelli,Tiziana Camerini,Rosalba Miceli,M G Di Mauro,Aurora Costa,Ettore Marubini,Michael B. Sporn,G. De Palo +10 more
TL;DR: Fenretinide induces a significant risk reduction of second breast cancer in premenopausal women, which is remarkable at younger ages, and persists several years after treatment cessation, and a trial in young women at high-risk is warranted.
Journal ArticleDOI
Activation of the second promoter of the transforming growth factor-beta 1 gene by transforming growth factor-beta 1 and phorbol ester occurs through the same target sequences.
Seong-Jin Kim,Fabienne Denhez,Kyung Young Kim,Jeffrey T. Holt,Jeffrey T. Holt,Michael B. Sporn,Anita B. Roberts +6 more
TL;DR: DNase I footprinting and gel mobility shift assays showed that binding to an Sp1 site and the putative TRE elements are required for maximal expression of the second promoter region of the TGF-beta 1 gene, suggesting that AP-1, which is capable of conferring phorbol ester or TGF
Journal Article
Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.
TL;DR: It is reported for the first time that a synthetic retinoid, N-(4-hydroxyphenyl)retinamide, can prevent the development of both primary and metastatic tumors in an animal model of metastasizing primary prostate cancer.